Back to all news
OpenEvidence Hits $12B Valuation as Clinical AI Adoption Surges, AI Chatbots Named Top 2026 Healthcare Hazard
OpenEvidence becomes the leading AI platform among U.S. physicians, securing a $12B valuation amid rising concerns about AI chatbot misuse in healthcare.
Key Details
- 1OpenEvidence raises $250M, now valued at $12B, doubling its valuation since October; exceeds $100M annual revenue.
- 2The platform's flagship product supported 18M U.S. physician consultations in December, up from 3M/month a year prior.
- 3Over 40% of U.S. doctors now use OpenEvidence, with 100M+ patients treated via its tools in 2025.
- 4Amazon launches an AI health assistant within its One Medical app, continuing Big Tech's push into clinical AI ecosystems.
- 5ECRI cites 'misuse of AI chatbots' as the #1 health tech hazard for 2026, highlighting serious risks in clinical settings.
Why It Matters
These developments exemplify both the rapid integration and scaling of clinical AI platforms and the urgent need for oversight to mitigate risks—especially as AI becomes more deeply embedded in healthcare. For radiology and imaging AI, these trends spotlight key adoption metrics, the growing ecosystem, and the importance of responsible deployment.
Source
HealthExec
Related News
•Cardiovascular Business
AI Enhances POCUS Cardiac Screening for Non-Cardiologists
An AI model accurately detects cardiac structural issues using point-of-care ultrasound (POCUS) images, even by non-cardiologists.
•Radiology Business
Aidoc Wins FDA Clearance for Comprehensive AI Triage Tool in Abdominal CT
Aidoc's Comprehensive Abdomen CT Triage tool receives FDA clearance to flag multiple conditions in a unified radiology workflow.
•Cardiovascular Business
FDA Clears AI Platform for Comprehensive Cardiac Risk Assessment on CT
HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.